Adaptimmune Therapeutics plc Stock News

Second-quarter earnings season continues with results from Disney, T-Mobile, Fox, ViacomCBS, and Clorox. Video-game makers Take-Two and Activision Blizzard also report. Plus, July jobs data.

In a year in which airlines have gotten hammered by the pandemic, a carrier with ultralow costs and flexible scheduling takes the lead. Not that the flight may not get a little rough.

Frappé de plein fouet par la crise que traverse le transport aérien, ADP réduit ses coûts et ses investissements pour revenir dans le vert dès 2021. Le groupe veut réduire la masse salariale et

Final earnings conference call transcript of ADP - ADP stock

The Pale Blue Portfolio prioritizes corporate responsibility and growth at a reasonable price. It limits the investing universe to companies that receive at least an A grade from MSCI's ESG database.

Selon le ministre délégué aux Transports Jean-Baptiste Djebbari, la crise sanitaire, qui a provoqué un effondrement du trafic aérien, impose de revoir "en profondeur" le projet d'extension du ter

Sens announcement for SPEAR REIT LIMITED – Results Of The Annual General Meeting - SENS

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 23, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medici

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and

Vident Investment Advisory LLC acquired a new stake in shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) in the second quarter, according to the company in its most recent 13F filing with the S

Zacks Investment Research upgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a hold rating to a buy rating in a report released on Tuesday morning, Zacks.com reports. Zacks Investment Rese

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) has earned an average rating of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat.com reports. Three equities re

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on T2 Biosystems (TTOO – Research Report).

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zogenix (ZGNX